PMEF
RIGL icon

Point72 Middle East FZE’s Rigel Pharmaceuticals RIGL Stock Holding History

Point72 Middle East FZE’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,103
Closed -$14.2K – 1807
2023
Q2 		$14.2K Sell
1,103
-263
-19% -$3.56K ﹤0.01% 1398
2023
Q1 		$18K Buy
1,366
+649
+91% +$10.3K ﹤0.01% 1437
2022
Q4 		$10.8K Buy
+717
New +$6.57K ﹤0.01% 1721

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Point72 Middle East FZE's RIGL Position: Q3 2023 in Review

Point72 Middle East FZE sold out of Rigel Pharmaceuticals (RIGL) in Q3 2023, closing a stake of 1,103 shares — an estimated $14.2K sold.

Point72 Middle East FZE first reported a position in RIGL in Q4 2022 and held it in 3 quarters. The position peaked at $18K in Q1 2023. 106 funds tracked by Wall St. Rank hold RIGL as of Q3 2023.

  • Point72 Middle East FZE reported no remaining Rigel Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 1,103 Rigel Pharmaceuticals shares in Q3 2023, an estimated $14.2K.
  • Point72 Middle East FZE first reported a position in Rigel Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Point72 Middle East FZE's Rigel Pharmaceuticals position peaked at $18K in Q1 2023.
  • 106 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2023.

Based on Point72 Middle East FZE's 13F filing for Q3 2023, filed 14 Nov 2023.